{"organizations": [], "uuid": "6cb087a9aa680dc123e1a02c8b0c00e6ef249edd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-amag-pharmaceuticals-announces-q1/brief-amag-pharmaceuticals-announces-q1-loss-per-share-1-59-idUSASC09ZGR", "country": "US", "domain_rank": 408, "title": "AMAG Pharmaceuticals Announces Q1 Loss Per Share $1.59", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.003, "site_type": "news", "published": "2018-05-03T19:12:00.000+03:00", "replies_count": 0, "uuid": "6cb087a9aa680dc123e1a02c8b0c00e6ef249edd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-amag-pharmaceuticals-announces-q1/brief-amag-pharmaceuticals-announces-q1-loss-per-share-1-59-idUSASC09ZGR", "ord_in_thread": 0, "title": "AMAG Pharmaceuticals Announces Q1 Loss Per Share $1.59", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "amag pharmaceuticals", "sentiment": "negative"}, {"name": "amag pharmaceuticals inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3 (Reuters) - AMAG Pharmaceuticals Inc:\n* AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND RAISES FULL YEAR FINANCIAL GUIDANCE\n* Q1 LOSS PER SHARE $1.59 * Q1 REVENUE $146.4 MILLION VERSUS I/B/E/S VIEW $151.8 MILLION\n* Q1 EARNINGS PER SHARE VIEW $-0.54 â€” THOMSON REUTERS I/B/E/S\n* AMAG PHARMACEUTICALS - SEES 2018 TOTAL REVENUE $540 MILLION - $580 MILLION\n* AMAG PHARMACEUTICALS - SEES 2018 GAAP OPERATING LOSS IN RANGE OF $128 MILLION - $108 MILLION\n* AMAG PHARMACEUTICALS - SEES 2018 NON-GAAP ADJUSTED EBITDA $120 MILLION - $140 MILLION Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T19:12:00.000+03:00", "crawled": "2018-05-04T16:49:06.006+03:00", "highlightTitle": ""}